Anti-atherosclerosis bionic nano delivery platform as well as preparation method and application thereof

By using bionic nanodelivery platform composed of black phosphorus nanosheets functionalized by double-ended amino polyethylene glycol and small interfering RNA, targeting macrophages, the problem of difficult targeting and defects in the prior art drugs are solved. , effectively inhibit and treat atherosclerosis.

CN118892467APending Publication Date: 2024-11-05XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202410974384.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

In the prior art, when treating atherosclerosis, drugs are difficult to target atherosclerosis plaques, defective macrophage burial action leads to disease progression, RNAi therapy cell uptake is low and has poor targeting, and cannot effectively inhibit atherosclerosis. .

Method used

Using a bionic nanodelivery platform composed of black phosphorus nanosheets functionalized by double-ended amino polyethylene glycol and small interfering RNA, it is coated through platelet membranes to target macrophages, restore cell burial and clear ROS, and inhibit inflammatory response. .

Benefits of technology

Targeting atherosclerotic plaques is achieved, restoring the burial effect of macrophages, significantly inhibiting the progress of atherosclerosis, reducing cholesterol deposition and inflammatory response, and improving the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118892467A_ABST
    Figure CN118892467A_ABST
Patent Text Reader

Abstract

The invention provides an anti-atherosclerosis bionic nano delivery platform as well as a preparation method and application thereof. The bionic nano delivery platform is prepared by mixing a double-end amino polyethylene glycol functionalized black phosphorus nanosheet, small interfering RNA (Ribonucleic Acid) and a platelet membrane, according to the application of the anti-atherosclerosis bionic nano delivery platform with the targeting capability in an atherosclerosis disease injection medicament, an atherosclerosis plaque region can be targeted through a platelet membrane and can be recognized and swallowed by macrophages; the microenvironment of atherosclerosis is continuously improved and the fibrous cap at the top of the plaque is continuously stabilized by utilizing the characteristic that small interfering RNA is used for recovering the interburial effect of macrophages and the high reaction activity of black phosphorus nanosheets and active oxygen. The anti-atherosclerosis bionic nano delivery platform with the targeting capability can provide a stable targeted drug delivery platform for tissue engineering application by promoting the interment effect of macrophages and continuous anti-oxidative stress.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedical nanomaterial preparation, and is specifically a preparation method and application of an anti-atherosclerotic biomimetic nano-delivery platform with targeting capability. The biomimetic nano-delivery platform is coated with a platelet membrane with the ability to target atherosclerotic plaques, and is internally filled with double-terminal amino-polyethylene glycol-functionalized black phosphorus nanosheets loaded with small interfering RNA. Background Art

[0002] Atherosclerosis (AS) is the main cause of coronary cardiovascular disease and one of the leading causes of death in humans. AS is a chronic inflammatory disease that usually originates from endothelial dysfunction. Subsequently, low-density lipoprotein (LDL) accumulates under the damaged endothelium, further promoting endothelial dysfunction, oxidative stress, and oxidative modification of trapped LDL (oxidized low-density lipoprotein, ox-LDL). Then, macrophages phagocytize ox-LDL and form foam cells inside the plaque. Ox-LDL can stimulate macrophages to produce a large amount of reactive oxygen species (ROS), further promoting the expression of proinflammatory factors such as interleukin (IL)-1β and IL-6, and exacerbating the inflammatory response within the plaque. The inflammatory response further induces apoptosis of endothelial cells, smooth muscle cells (SMCs), and leukocytes, and produces a large amount of cell debris and extracellular matrix. Due to defective efferocytosis, these cells are inefficiently cleared. The extracellular matrix formed by SMC wraps them, forming a fibrous cap on the top and a necrotic core of the plaque inside. In the late stage of AS, matrix metalloproteinases secreted by inflammatory cells cause the fibrous cap to loosen, leading to acute cardiovascular events. Currently, drug therapy is a common treatment for AS. However, systemic administration cannot achieve satisfactory therapeutic effects due to rapid drug clearance and poor accumulation in lesions, which is mainly attributed to complex reasons such as oxidative stress, inflammatory response and macrophage efferocytosis defects.

[0003] Effeculation is the biological process in which cells with phagocytic ability (such as macrophages) engulf apoptotic cells, and it actively participates in maintaining the homeostasis of tissues and organs by reducing the harmful effects of cell death. Macrophage-led efferocytosis can inhibit the accumulation of foam cells in AS plaques, thereby indirectly offsetting the ROS and proinflammatory mediators produced by foam cells and limiting the progression of atherosclerosis. Specific signal activation of macrophages can generally affect the progression of the disease, which is more obvious in AS. Studies have shown that defects in macrophage efferocytosis lead to the formation of a necrotic core in AS. As the necrotic core grows and the fibrous cap becomes thinner, the plaque becomes more susceptible to rupture. Therefore, it is necessary to develop a safe and effective drug to treat AS.

[0004] RNA interference (RNAi) therapy has created a new treatment modality by mediating specific gene knockdown. A variety of nano-delivery platforms have been developed to deliver RNA to the whole body for disease treatment, including small interfering RNA (siRNA). siRNA is a double-stranded RNA molecule of 21-23 nucleotides in length that exerts its effects at the post-transcriptional level. siRNA molecules are generally specific and effective and can knock out disease-related genes. The US Food and Drug Administration has approved three siRNA drugs for clinical treatment. Although a variety of nanoparticle-based siRNA delivery platforms have been developed, their use in targeting macrophages in AS has not been confirmed by a large number of studies. Calmodulin-dependent protein kinase gamma (Ca2+) is a key regulator of AS. 2+ CaMKIIγ is a protein expressed by macrophages. It promotes the transformation of fibrous AS into necrotic lesions with thin fibrous caps, which induces acute atherothrombotic vascular events including myocardial infarction, sudden coronary death, and unstable angina. This is because CaMKIIγ blocks the key pathway of efferocytosis, protective activation of transcription factor 6 (ATF6) / liver X receptor alpha (LXRα) / c-Mer proto-oncogene tyrosine kinase (MerTK). Defective macrophage efferocytosis leads to the inability to clear apoptotic cells in time, triggering secondary necrosis, inducing inflammatory response, and accelerating the thinning of the fibrous cap. Therefore, we envisioned silencing CaMKIIγ encoded by the macrophage gene Camk2g through siRNA in order to restore macrophage efferocytosis to treat AS.

[0005] Although RNAi therapy has broad prospects, its cellular uptake is low, it is easily degraded by nucleases, easily cleared by the phagocytic system, and has poor AS targeting. Therefore, siRNAs require carriers to protect them and effectively deliver them to target cells. In clinical trials for diseases such as metabolic diseases, hematology, infectious diseases, and oncology, a variety of nanoparticle-based siRNA delivery platforms have been developed. Black phosphorus nanosheets (BPNSs) have a multilayer folded structure and are ideal carriers for loading chemotherapeutic drugs, peptides, and nucleic acids. More importantly, BPNSs have excellent ROS responsiveness, can significantly remove excess ROS in cells, alleviate oxidative stress, and then inhibit the activation of subsequent inflammatory response chains. Therefore, BPNSs are widely used in diabetic skin wounds, bone regeneration, and cardiovascular diseases. Summary of the invention

[0006] In view of the problems existing in the prior art, the present invention provides an anti-atherosclerosis bionic nano-delivery platform and a preparation method and application thereof; the bionic nano-delivery platform has good targeting ability, macrophage burial restoration effect and anti-oxidative stress ability; the bionic nano-delivery platform can be used as an intravenous injection drug to automatically target atherosclerotic plaques in the blood circulation; in the microenvironment of atherosclerotic plaques, the bionic nano-delivery platform can target macrophages and be engulfed by them, and then small interfering RNA plays a role in restoring macrophage burial, black phosphorus nanosheets play an anti-oxidative stress and anti-inflammatory effect, and the high ROS reaction activity of the black phosphorus nanosheets can achieve the maximum degree of ROS clearance in the microenvironment area of ​​atherosclerotic plaques, achieve effective improvement of the microenvironment of atherosclerotic plaques, reduce cholesterol deposition and inflammatory response, significantly promote the burial effect of macrophages, and effectively inhibit the progression of atherosclerosis.

[0007] In order to achieve the above technical objectives, the present invention provides an anti-atherosclerotic bionic nano-delivery platform, characterized in that: the bionic nano-delivery platform is a concentration of 1.0 to 2.5 mg mL -1 Dispersion of black phosphorus nanosheets functionalized with double-terminated amine polyethylene glycol, concentration 0.2-0.5 nmol mL -1 The small interfering RNA (siRNA) solution and platelet membrane are mixed and prepared; the concentration is 1.0-2.5 mg mL -1 Dispersion of black phosphorus nanosheets functionalized with double-terminated amine polyethylene glycol, concentration 0.2-0.5 nmol mL -1 The volume ratio of the small interfering RNA solution to the platelet membrane is 1 to 2:1:1;

[0008] Wherein, the concentration is 1.0~2.5mg mL -1The dispersion of black phosphorus nanosheets functionalized with double-terminated PEG is prepared by adding double-terminated PEG to a concentration of 1.0 to 2.5 mg mL -1 The black phosphorus nanosheet dispersion is stirred in a dark environment for 6 to 8 hours at room temperature with a pH value of 8.0 to 9.0; wherein the mass ratio of the double-terminated amino polyethylene glycol to the black phosphorus nanosheet is 2 to 10:1 to 2.5;

[0009] The concentration is 0.2-0.5 nmol mL -1 The small interfering RNA solution is a mixture of small interfering RNA and 1 mmol mL -1 The small interfering RNA is fully dissolved in Tris-HCl buffer, wherein the molar mass ratio of the small interfering RNA to the Tris-HCl buffer is 0.2-0.5:1.

[0010] A further technical solution of the present invention is as follows: the platelet membrane is obtained by collecting blood from C57BL / 6 mice, centrifuging at a centrifugal speed of 100-120g for 15-20 minutes to collect the supernatant, then centrifuging at a centrifugal speed of 800-1000g for 15-20 minutes to precipitate platelets, resuspending the platelets in PBS containing 1mM EDTA and protease inhibitors, and then repeatedly freezing and thawing the platelet membrane by centrifuging at a centrifugal speed of 8000-10000g for 10-20 minutes.

[0011] A further technical solution of the present invention is as follows: the black phosphorus nanosheets are synthesized by electrochemically exfoliating black phosphorus crystal blocks; the bionic nano delivery platform is firstly prepared by mixing the black phosphorus nanosheets with a concentration of 1.0 to 2.5 mg mL -1 Dispersion of black phosphorus nanosheets functionalized with double-terminated amine polyethylene glycol and concentration of 0.2-0.5 nmol mL -1 The small interfering RNA solution is stirred at room temperature for 5 to 8 hours to mix evenly, and then centrifuged at a centrifugal speed of 5000 to 12000 rpm for 15 to 20 minutes, and filtered to obtain black phosphorus nanosheets loaded with small interfering RNA; then the black phosphorus nanosheets loaded with small interfering RNA are mixed with platelet membranes, and then ultrasonically treated for 2 to 4 minutes at a frequency of 40 to 50 kHz and a power of 100 to 120 W in an ultrasonic water bath, and fused 20 to 30 times through a micro extruder, and then centrifuged at a centrifugal speed of 3000 to 5000 g for 15 to 30 minutes to remove the uncoated membrane, and finally centrifuged at a centrifugal speed of 8000 to 10000 g for 10 to 20 minutes to obtain an anti-atherosclerosis bionic nano delivery platform with targeting ability.

[0012] A further technical solution of the present invention is that the small interfering RNA has the following sequence:

[0013] Sense strand: 5′-AAC GUG GUA CAU AAU GCU ACA-3′

[0014] Antisense strand: 5′-UGU AGC AUU AUG UAC CAC GUU-3′.

[0015] The present invention also provides a method for preparing an anti-atherosclerosis bionic nano-delivery platform, which specifically comprises the following steps:

[0016] (1) Precipitate and disperse black phosphorus nanosheets in ultrapure water to obtain a concentration of 1.0 to 2.5 mg mL -1 A dispersion of black phosphorus nanosheets functionalized with double-terminal amino polyethylene glycol is prepared, and then the pH value is adjusted to 8.0-9.0, and then double-terminal amino polyethylene glycol powder is slowly added, and the mixed solution is continuously stirred for 6-8 hours at room temperature in the dark, and after stirring, the mixture is centrifuged at 4-10° C. and 5000-12000 rpm for 15-20 minutes, the supernatant is discarded, and the precipitate is washed to form black phosphorus nanosheets functionalized with double-terminal amino polyethylene glycol; wherein the mass ratio of double-terminal amino polyethylene glycol powder to black phosphorus nanosheets is 2-10:1-2.5;

[0017] (2) Small interfering RNA with a concentration of 1 mmol mL -1 Dissolve the Tris-HCl buffer to a concentration of 0.2-0.5 nmol mL -1 siRNA solution;

[0018] (3) mixing the double-terminated amino-polyethylene glycol-functionalized black phosphorus nanosheet dispersion prepared in step (1) and the small interfering RNA solution prepared in step (2) in a volume ratio of 1 to 2:1, stirring at room temperature for 5 to 8 hours, centrifuging at a centrifugal speed of 5000 to 12000 rpm for 15 to 20 minutes, and then filtering to obtain black phosphorus nanosheets loaded with small interfering RNA;

[0019] (4) Platelet membranes were prepared by extracting platelets from C57BL / 6 mice and repeated freeze-thaw cycles;

[0020] (5) The black phosphorus nanosheet loaded with small interfering RNA prepared in step (3) and the platelet membrane prepared in step (4) are mixed in a volume ratio of 1 to 2:1, ultrasonically treated in an ultrasonic water bath at a frequency of 40 to 50 kHz and a power of 100 to 120 W for 2 to 4 minutes, and fused 20 to 30 times by a micro extruder; then, the uncoated membrane is removed by centrifugation at a centrifugal speed of 3000 to 5000 g for 15 to 30 minutes, and finally, the anti-atherosclerotic bionic nano-delivery platform with targeting capability is obtained by centrifugation at a centrifugal speed of 8000 to 10000 g for 10 to 20 minutes.

[0021] A preferred technical solution of the present invention: the black phosphorus nanosheets in step (1) are synthesized by electrochemical stripping of black phosphorus crystal blocks; and an ammonia solution is added in step (1) to adjust the pH to 8.0-9.0.

[0022] A preferred technical solution of the present invention: The specific preparation process of the platelet membrane in step (4) is: collect blood from C57BL / 6 mice, centrifuge at a centrifugal speed of 100-120g for 15-20 minutes, collect the supernatant, and then centrifuge at a centrifugal speed of 800-1000g for 15-20 minutes to precipitate platelets, and resuspend the precipitated platelets in PBS containing 1mM EDTA and protease inhibitors, repeat freeze-thaw cycles 3-5 times, and finally centrifuge at a centrifugal speed of 8000-10000g for 10-20 minutes to obtain the platelet membrane.

[0023] The present invention also provides an application of an anti-atherosclerotic bionic nano-delivery platform in drugs for treating atherosclerotic diseases.

[0024] A further technical solution of the present invention is to use the anti-atherosclerotic bionic nano-delivery platform in the preparation of an intravenous injection for treating atherosclerotic diseases.

[0025] The preferred technical solution of the present invention is that the anti-atherosclerotic bionic nano-delivery platform is used as a single substance of an atherosclerotic disease injection agent, and the single dosage of the injection agent is 100-120 μL, and the concentration is 1.0-1.5 mg / kg -1 .

[0026] The present invention uses BPNSs modified with double-terminal amino polyethylene glycol (PEG) to load siRNA (PBP@siR), and uses its small size to be easily taken up by cells to achieve siRNA delivery; then the synthesized nano delivery system PBP@siR is coated with platelet membrane (PM) to prepare a bionic nano delivery platform PBP@siR@PM with a shell-core structure. The anti-atherosclerosis bionic nano delivery platform with targeting ability in the present invention can be directly injected by intravenous injection. After intravenous injection, PM targets the damaged endothelium through the interaction between the GP Ib-IX-V complex and the exposed subendothelial von Willebrand factor (von Willebrand factor, vWF) and platelet receptors (GPVI and integrin α2β1) and collagen. After reaching the plaque environment, the interaction between platelet CD62P and PSGL-1 on monocytes / macrophages enables PBP@siR@PM to cross the damaged endothelium into the plaque and be engulfed by inflammatory macrophages. The siRNA of PBP@siR@PM is then released into the cytoplasm to promote efferocytosis. - / - In mice, the biomimetic nano-delivery platform PBP@siR@PM can effectively target inflammatory macrophages. The biomimetic nano-delivery platform PBP@siR@PM alleviated cholesterol deposition and inflammatory response, significantly promoted macrophage efferocytosis, and effectively inhibited the progression of AS.

[0027] The beneficial effects of the present invention are as follows: (1) the biomimetic nano-delivery platform of the present invention has good targeting ability, restores macrophage efferocytosis and anti-oxidative stress ability;

[0028] (2) The bionic nano-delivery platform of the present invention can be used as an intravenous drug to automatically target atherosclerotic plaques in the blood circulation; in the microenvironment of atherosclerotic plaques, the bionic nano-delivery platform can target macrophages and be engulfed by them, and then the small interfering RNA plays a role in restoring macrophage efferocytosis, and the black phosphorus nanosheets exert anti-oxidative stress and anti-inflammatory effects.

[0029] (3) The high ROS reactivity of the black phosphorus nanosheets in the present invention can achieve the maximum degree of ROS clearance in the microenvironment of atherosclerotic plaques, inhibit the occurrence of the oxidative stress reaction chain from the source; achieve effective improvement of the microenvironment of atherosclerotic plaques, reduce cholesterol deposition and inflammatory response, significantly promote the efferocytosis of macrophages, and effectively inhibit the progression of atherosclerosis.

[0030] The present invention can provide a stable biological targeting platform for tissue engineering applications by restoring macrophage efferocytosis and anti-oxidative stress effects; the strategy of loading small interfering RNA that can restore macrophage efferocytosis onto black phosphorus nanosheets with anti-oxidative stress effects and then coating them with platelet membranes with targeted effects provides new insights into the design of tissue engineering biomaterials. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1-1 Atomic force microscopy images of BPNSs;

[0032] Figure 1-2 Thickness curve of BPNSs measured by atomic force microscope;

[0033] Figure 2 Comparison of Raman spectra of BPNSs and BP@PEG

[0034] Figure 3 Schematic diagram of the comparison of representative TEM images of BPNSs, PM and PBP@siR@PM;

[0035] Figure 4 Schematic diagram of the comparison of XRD images of BPNSs and PBP@siR@PM;

[0036] Figure 5 Schematic diagram of the comparison of hydrodynamic diameters of BPNSs, BP@PEG, PBP@siR,PM and PBP@siR@PM;

[0037] Figure 6 Schematic diagram of the comparison of Zeta potential of PM, BPNSs, BP@PEG, PBP@siR and PBP@siR@PM;

[0038] Figure 7 Schematic diagram of UV-visible absorbance spectra of siRNA, BP@PEG and PBP@siR@PM;

[0039] Figure 8 Schematic diagram for comparison of encapsulation efficiency of PBP@siR and PBP@siR@PM;

[0040] Fig. 9 Schematic diagram of the comparison of siRNA release curves of PBP@siR@PM over time in H2O2 and PBS environments;

[0041] Fig.10 SDS-PAGE images and characteristic protein expressions of proteins in PM, PBP@PM, and PBP@siR@PM;

[0042] Fig.11Schematic diagram of the comparison of cell viability of HUVEC and RAW264.7 in different treatment groups detected by CCK-8;

[0043] Fig.12 Schematic diagram of the comparison of fluorescence intensity of Free siRNA and PBP@siR@PM at different times after being engulfed by inflammatory macrophages using flow cytometry;

[0044] Fig.13 Representative pictures of subcellular localization of PBP@siR@PM at different times after being engulfed by Hela cells;

[0045] Fig.14 Comparison of intracellular ROS generation and corresponding fluorescence intensity in LPS-induced macrophages after treatment with Control, LPS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM;

[0046] Fig.15 Schematic diagram of the comparison of IL-10 and IL-6 levels and corresponding fluorescence intensities of LPS-induced macrophages after treatment with Control, LPS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM;

[0047] Figure 16-1 This is a flow cytometry comparison of the apoptosis of LPS-induced macrophages after treatment with Control, LPS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM;

[0048] Figure 16-2 This is a statistical analysis view of the apoptosis of LPS-induced macrophages after treatment with Control, LPS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM by flow cytometry;

[0049] Fig.17 Schematic diagram of the comparison of optical microscopy images of Ox-LDL-induced foam cell formation in macrophages after treatment with Control, Ox-LDL, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM;

[0050] Fig.18 Schematic diagram of flow cytometry detection of the ability of LPS-induced macrophages to phagocytize DiO-labeled apoptotic cells after treatment with Control, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM;

[0051] Fig.19Western blot was used to detect the expression of CaMKIIγ and MerTK, the efferocytosis-related proteins in LPS-induced macrophages after treatment with Control, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM;

[0052] Fig. 20 is a schematic diagram of the timeline of the animal experiment in the embodiment;

[0053] Fig.21 Schematic diagram of drug metabolism curve comparison of Free siRNA, PBP@siR and PBP@siR@PM in AS mice;

[0054] Figure 22-1 Schematic diagram of the comparison of the distribution fluorescence intensity of PBP@siR and PBP@siR@PM in the aorta of AS mice;

[0055] Figure 22-2 Schematic diagram of the statistical analysis and comparison of the distribution fluorescence intensity of PBP@siR and PBP@siR@PM in the aorta of AS mice;

[0056] Figure 23-1 Schematic diagram showing the comparison of representative images of the gross Oil Red O staining of the aorta of AS mice in the PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0057] Figure 23-2 Schematic diagram of the statistical analysis and comparison of the percentage of plaques stained with Oil Red O in the aorta of AS mice in the PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0058] Fig.24 Schematic diagram showing the Oil Red O, H&E and Masson staining of the aorta root of AS mice in the PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0059] Figure 25-1 Schematic diagram of DHE staining and fluorescence intensity comparison of aortic root of AS mice in PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0060] Figure 25-2 Schematic diagram of DHE staining and fluorescence intensity statistical analysis of aortic roots of AS mice in PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0061] Figure 26-1Schematic diagram of CD68 / TNF-α staining and fluorescence intensity comparison of aortic roots of AS mice in PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0062] Figure 26-2 Schematic diagram of CD68 / TNF-α staining and fluorescence intensity statistical analysis of aortic roots of AS mice in PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0063] Figure 27-1 Schematic diagram of CD68 / c-caspase-3 staining and fluorescence intensity comparison of aortic roots of AS mice in PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0064] Figure 27-2 Schematic diagram of CD68 / c-caspase-3 staining and fluorescence intensity statistical analysis of AS mouse aorta root in PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0065] Figure 28-1 Schematic diagram of Western blot detection of the expression of inflammation-related proteins in aortic plaques of AS mice in PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0066] Figure 28-2 Schematic diagram of the comparison of statistical analysis of the expression of inflammation-related proteins in aortic plaques of AS mice in the PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups detected by Western blot;

[0067] Figure 29-1 Schematic diagram of CD68 / CaMKIIγ staining and fluorescence intensity comparison of aortic roots of AS mice in PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0068] Figure 29-2 Schematic diagram of CD68 / CaMKIIγ staining and fluorescence intensity statistical analysis of AS mouse aorta root in PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0069] Figure 30-1 Schematic diagram of MerTK staining and fluorescence intensity comparison of aortic roots of AS mice in PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0070] Figure 30-2 Schematic diagram of the comparison of MerTK staining and fluorescence intensity statistical analysis of the aortic root of AS mice in the PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups;

[0071] Figure 31-1 Schematic diagram of the comparison of CaMKIIγ and MerTK protein expressions in aortic plaques of AS mice in PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups detected by Western blot;

[0072] Figure 31-2 is a comparative diagram of the statistical analysis of CaMKIIγ and MerTK protein expressions in aortic plaques of AS mice in the PBS, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM groups detected by Western blot;

[0073] Fig.32 It is a schematic diagram of the experimental design process of the present invention. DETAILED DESCRIPTION

[0074] The present invention is further described below in conjunction with embodiments. The technical solutions shown in the accompanying drawings are specific solutions of the embodiments of the present invention and are not intended to limit the scope of the invention to be protected. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0075] The embodiment provides an anti-atherosclerosis biomimetic nano-delivery platform with targeting capability, and the preparation process thereof is as follows: Fig.32 As shown, the specific steps include:

[0076] (1) Black phosphorus nanosheets (BPNSs) were synthesized by electrochemical exfoliation of black phosphorus crystal blocks. The BPNSs were precipitated and dispersed in ultrapure water at a concentration of 2.5 mg mL -1 ; Then, an ammonia solution was added to adjust the pH to 8.0, and then 10 mg of double-terminated amino polyethylene glycol powder was slowly added. The mixed solution was stirred continuously for 6 hours at room temperature in the dark. After stirring, it was centrifuged at 12000 rpm for 15 minutes at 4°C, the supernatant was discarded, and the precipitate was washed to form double-terminated amino polyethylene glycol functionalized black phosphorus nanosheets (BP@PEG);

[0077] (2) Concentration 0.2 nmol mL -1 The siRNA solution was prepared by mixing 0.2 nmol siRNA with 1 mmol mL -1The mixture was mixed with Tris-HCl buffer and fully dissolved to obtain; then the double-terminal amino polyethylene glycol functionalized black phosphorus nanosheet dispersion prepared in step (1) and the siRNA solution were mixed in a volume ratio of 1:1 to 2:1, stirred at room temperature for 5 hours, centrifuged at 12000 rpm for 15 minutes, and filtered to obtain the siRNA-loaded black phosphorus nanosheet (PBP@siR);

[0078] (3) Blood from C57BL / 6 mice was collected and centrifuged at 100 g for 20 minutes to collect the supernatant. Platelets were then precipitated by centrifugation at 800 g for 20 minutes and resuspended in PBS containing 1 mM EDTA and protease inhibitors. After three freeze-thaw cycles, platelet membranes (PMs) were obtained by centrifugation at 8000 g for 10 minutes.

[0079] (4) The BP@PEG prepared in step (1) or the PBP@siR prepared in step (2) and the PM prepared in step (3) were mixed at a volume ratio of 1:1, and then ultrasonically treated for 2 minutes at a frequency of 40 kHz and a power of 100 W in an ultrasonic water bath, and fused 20 times by a micro extruder. Subsequently, the uncoated membrane was removed by centrifugation at 3000 g for 30 minutes, and the PBP@PM without siRNA loading and the anti-atherosclerotic biomimetic nanodelivery platform PBP@siR@PM with targeting ability were obtained by centrifugation at 8000 g for 10 minutes.

[0080] Name of the siRNA described in the examples: Ca2+ / calmodulin-dependent protein kinaseγ (CaMKIIγ) siRNA (m)

[0081] siRNA: siCamK2g, the specific sequence is as follows:

[0082] Sense 5′-AAC GUG GUA CAU AAU GCU ACA-3′

[0083] Antisense 5′-UGU AGC AUU AUG UAC CAC GUU-3′.

[0084] The inventors of the present application conducted the following experimental studies on the performance of siRNA, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM in the above Example 1.

[0085] Experiment 1: Atomic force microscopy (AFM) was used to characterize the morphology and thickness of BPNSs. Figure 1-1 As shown, microscopic thickness analysis is Figure 1-2 As shown, the thickness of BPNSs is about 6.835 nm.

[0086] Experiment 2: In order to study the effect of PEG modification on the two-dimensional layered structure of black phosphorus nanosheets, the inventors of this application conducted Raman characterization on BPNs and BP@PDA in the examples; Raman generally has A 1 g , B 2g , A g 2 Three characteristic vibration peaks, Raman spectrum (such as Figure 2 ) shows that BPNs and BP@PDA are approximately 365, 440, and 465 cm -1 There are three significant characteristic vibration peaks at 1 g , B 2g , A g 2 Three vibration modes; the peak displacement basically did not move, confirming that the two-dimensional structure of black phosphorus nanosheets was not changed after PEG modification. BP@PEG was at 2800-3000cm -1 A new absorption peak appeared in the range, which was the result of PEG modification.

[0087] Experiment 3: The BPNSs, PM and PBP@siR@PM in Example 1 were observed by transmission electron microscopy (TEM). Figure 3 It was shown that BPNs and BP@PDA nanosheets were two-dimensional multilayered sheet structures with a diameter of about 0.5-2 μm. PM had a spherical structure, which successfully encapsulated PBP@siR to form a typical core-shell structure.

[0088] Experiment 4: In order to study the crystal form and crystal state of the prepared BPNSs and PBP@siR@PM, the inventors of the present application conducted X-ray powder diffraction (XRD) analysis. Figure 4 The results show that BPNSs and PBP@siR@PM have high and sharp characteristic diffraction peaks, proving their excellent crystallinity, and basically coincide with the XRD diffraction peaks of the standard black phosphorus block (JCPDS No.73-1358). The positions of the characteristic diffraction peaks of BPNSs and PBP@siR@PM have not changed, indicating that no new lattice has been formed and the original black phosphorus crystal type is maintained.

[0089] Experiment 5: The surface hydrodynamic diameters of BPNSs, BP@PEG, PBP@siR, PM and PBP@siR@PM were determined by dynamic light scattering (DLS). Figure 5 ) and Zeta potential ( Figure 6 ). The test results are as follows Figure 5 and Figure 6As shown in the figure, PM coating increased the hydrodynamic diameter of PBP@siR from 104.3nm to 140.0nm, indicating that PM was successfully coated on the surface of PBP@siR. The zeta potentials were -21.7mV, -9mV, -14.4mV, -26.2mV, and -25.7mV, respectively. After PM coating, the zeta potential of PBP@siR changed from -14.4mV to -25.7mV.

[0090] Experiment 6: To prove the successful loading of siRNA, UV-visible spectroscopy was performed on siRNA, BP@PEG and PBP@siR@PM. The results of UV-visible spectroscopy are shown in the figure. Figure 7 As shown, it was found that the absorption peak of PBP@siR@PM at 260 nm was higher than that of BP@PEG. This is because siRNA has a characteristic absorption peak at 260 nm.

[0091] Experiment 7: The fluorescence intensity of siRNA in the supernatant after preparing PBP@siR and PBP@siR@PM was measured by spectrophotometer, and compared with the fluorescence intensity of siRNA at the original added concentration to determine the encapsulation efficiency of siRNA ( Figure 8 The results showed that the encapsulation efficiency of PBP@siR and PBP@siR@PM was 72.8% and 68.9%, respectively, and the two had similar encapsulation efficiency. The prepared PBP@siR@PM was stirred in H2O2 and PBS, and the supernatant was collected after centrifugation at a predetermined time point. The concentration of siRNA released in the supernatant was quantified by a spectrophotometer. The test results are shown in Fig. 9 As shown, under physiological environment (PBS), PBP@siR@PM has the smallest release rate, while in H2O2 environment, its release efficiency gradually increases with time and reaches 76.5% at 600 min.

[0092] Experiment 8: To further confirm that PM successfully functionalized PBP@siR, SDS-PAGE was used to analyze the proteins of PBP@siR@PM and PBP@PM. The analysis results are as follows: Fig.10 , the results showed that most of the PM proteins were successfully transferred.

[0093] Experiment 9: In order to achieve safe and effective application in cells, we tested the cell activity of HUVEC and RAW264.7 cell lines after applying the biomimetic nano-delivery platform. After adding BP@PEG, PBP@PM, PBP@siR or PBP@siR@PM to the culture medium for co-incubation, the test results are as follows: Fig.11 As shown, CCK-8 cell viability assay demonstrated that the viability of HUVEC and RAW264.7 cells in different material environments had no significant difference from that in the PBS group.

[0094] Experiment 10: To further verify the ability of inflammatory macrophages to take up PBP@siR@PM, we used flow cytometry to detect the fluorescence intensity at different times. The test results are as follows: Fig.12 As shown in the figure, the fluorescence intensity of PBP@siR@PM in inflammatory macrophages gradually increased with the increase of incubation time. The fluorescence intensity of the Free siRNA group did not show significant changes. In order to track the intracellular siRNA release behavior of PBP@siR@PM, we co-incubated Cy5.5-labeled Free siRNA and PBP@siR@PM with Hela cells, and then used LysoTracker Green to stain lysosomes. The staining results are shown in the figure. Fig.13 As shown in the figure, the cellular uptake of PBP@siR@PM gradually increased with the extension of incubation time, while FreesiRNA could hardly enter the cells after 24 hours of incubation. After 4 hours of incubation with Hela cells, the red fluorescence of PBP@siR@PM overlapped with the green fluorescence of the lysosomal probe. This indicates that PBP@siR@PM is located in endosomes or early lysosomes. Subsequently, after the incubation was extended to 24 hours, the red and green fluorescence signals were clearly separated. This proves that PBP@siR@PM can escape from lysosomes smoothly.

[0095] Experiment 11: To prove that BPNSs can inhibit the production of ROS in macrophages, we used DCFH-DA fluorescent dye to observe the level of ROS. Fig.14 As shown in the figure, in the LPS group, the ROS level was significantly increased. In the treatment groups with BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM, the fluorescence signal intensity was significantly reduced, much lower than that of the LPS group, showing that BPNSs have a strong ROS scavenging ability. Next, we used immunofluorescence co-localization staining to detect the ability of BPNSs to inhibit the inflammatory response of macrophages. The test results are shown in Figure 2. Fig.15 As shown in Figure 16, after LPS treatment, macrophages showed strong red fluorescence representing the pro-inflammatory cytokine IL-6. After treatment with BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM, the red fluorescence was significantly reduced, while the green fluorescence representing the anti-inflammatory cytokine IL-10 was strong. In order to further verify the protection of BPNSs on macrophages, we detected the cell apoptosis in different treatment groups. The test results are shown in Figure 16. As we expected, the apoptosis of macrophages treated with BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM was significantly lower than that in the LPS group. It can be seen that BPNSs inhibits the oxidative stress of macrophages by reacting with ROS, thereby reducing the inflammatory response and significantly inhibiting their entry into the apoptosis process.

[0096] Experiment 12: To explore whether PBP@siR@PM affects the formation of foam cells, we treated inflammatory macrophages with ox-LDL to induce foam cell formation. Fig.17 As shown in the figure, in the ox-LDL group, after 12 hours of ox-LDL treatment, Oil Red O (ORO) staining showed obvious intracellular lipid droplets and the formation of a large number of foam cells. When these cells were treated with BP@PEG and PBP@PM, the formation of foam cells decreased, which may be due to the efficient scavenging of ROS and anti-inflammatory effects of BPNSs. In the PBP@siR and PBP@siR@PM treatment groups, the formation of foam cells was significantly inhibited. Compared with the BP@PEG and PBP@PM groups, the reason for the more effective inhibition of foam cell formation may be that siRNA can promote macrophage efferocytosis.

[0097] Experiment 13: To further verify the effect of siRNA on promoting macrophage phagocytosis, we co-incubated DiO-labeled apoptotic cells with macrophages treated with Control, BP@PEG, PBP@PM, PBP@siR and PBP@siR@PM, and then detected the ability of macrophages to phagocytose apoptotic cells by flow cytometry. The test results are shown in the figure. Fig.18 As shown, the results showed that in the PBP@siR and PBP@siR@PM treatment groups, the phagocytic ratio of apoptotic cells reached 20.37% and 26.17%, which were significantly higher than those in the BP@PEG and PBP@PM treatment groups.

[0098] Experiment 14: Western blot was used to detect the expression of siRNA-targeted inhibitory protein CaMKIIγ. The test results are as follows: Fig.19 As shown in the figure, the data showed that CaMKIIγ was decreased in the PBP@siR and PBP@siR@PM treated groups. In addition, the decrease in CaMKIIγ increased the expression of the downstream MerTK protein. Therefore, we also evaluated the expression of MerTK and found that it was significantly increased in PBP@siR and PBP@siR@PM treated macrophages. Therefore, siRNA can be successfully delivered to macrophages and promote efferocytosis by inhibiting CaMKIIγ expression and increasing MerTK expression.

[0099] Experiment 15: Animal experiment was conducted by tail vein injection. ApoE was fed with a high-fat diet (HFD) - / - After 8 weeks, the experimental group was given corresponding treatment, and the PBS group was injected with an equal volume of PBS as a control. The animals were euthanized at different time points for subsequent studies (experimental process as shown in Fig. 20). The pharmacokinetic characteristics of PBP@siR@PM in mice were studied. Cy5.5 was labeled on siRNA to prepare PBP@siR and PBP@siR@PM. Within 24 hours after intravenous injection, the fluorescence intensity in the blood was measured at the specified time. The results are shown in Fig.21 As shown, the results showed that the two nano-delivery platforms can prolong the circulation time of siRNA. Compared with the rapid clearance of Free siRNA within 30 minutes, the half-life of PBP@siR is about 1 hour, and the half-life of PBP@siR@PM is about 2.5 hours. This can improve the in vivo localization and plaque accumulation of PBP@siR@PM.

[0100] Experiment 16: To test the targeting of PBP@siR and PBP@siR@PM to atherosclerotic plaques, ApoE - / - Atherosclerosis was induced in mice. Cy5.5-labeled PBP@siR or PBP@siR@PM was administered to these mice by intravenous injection, and then the aorta was harvested 12 hours after injection and compared. The comparison results are shown in Figure 22-1 and Figure 22-2 As shown in the figure, the in vitro imaging showed that the fluorescence of the isolated aorta in the PBP@siR@PM group was stronger, about twice that of the PBP@siR group, indicating that PBP@siR@PM has good targeting ability to atherosclerotic aorta.

[0101] Experiment 17: To evaluate the effect of PBP@siR@PM in treating AS, we fed ApoE - / - The mice were divided into PBS, BP@PEG, PBP@siR, PBP@PM and PBP@siR@PM groups. After 4 weeks of treatment, the aorta and aortic valve ring were obtained for relevant tests. Aortic oil red O (ORO) staining showed ( Figure 23-1 ), the staining area in PBP@PM and PBP@siR@PM groups was very low. Further quantitative analysis ( Figure 23-2 ), the average plaque area of ​​the PBP@PM and PBP@siR@PM groups was 16.91% and 8.12% respectively. Similar results were also found in the Oil Red O staining of the aortic root annulus sections. Fig.24As shown, the effective anti-atherosclerotic activity of PBP@PM and PBP@siR@PM was demonstrated. Subsequently, we evaluated the necrotic core and collagen concentration by hematoxylin and eosin (H&E) and Masson's trichrome staining of the aortic root. The PBS group showed a large necrotic core, indicating advanced lesions. In contrast, the necrotic core was reduced in the PBP@PM and PBP@siR@PM groups. Consistent with this result, Masson's trichrome staining found that the collagen concentration in the PBP@PM and PBP@siR@PM groups increased. In contrast, the BP@PEG and PBP@siR groups did not show satisfactory therapeutic effects in either the aorta or the aortic root. This is due to their lack of targeting and inability to exert therapeutic effects within the plaque. The above results indicate that the PM-encapsulated nanodelivery platform can achieve better therapeutic effects. Both the PBP@PM and PBP@siR@PM groups inhibited AS by stabilizing the further development of plaques.

[0102] Experiment 18: To explore the in vivo therapeutic mechanism of AS, we performed dihydroethylammonium (DHE) staining on the aortic roots obtained from AS mice to assess their ROS levels. The staining results are shown in Figure 25-1 The staining statistics are as follows: Figure 25-2 . As can be seen from the attached figure, strong red fluorescence was observed in the PBS group, indicating that high levels of ROS were produced in these aortic tissues. ROS fluorescence was also strong in the BP@PEG and PBP@siR groups. In contrast, the aortic ROS signals in the PBP@PM and PBP@siR@PM groups were significantly weakened. Excessive ROS aggravates the inflammatory response. We used CD68 / TNF-α immunofluorescence co-localization in the aortic root to evaluate the inflammatory condition. Figure 26-1 and Figure 26-2 As shown in Figure 2, the results showed that compared with the PBS, BP@PEG and PBP@siR groups, the TNF-α red fluorescence in the PBP@PM and PBP@siR@PM groups was significantly reduced. The CD68 / c-caspase-3 immunofluorescence co-localization also showed the same results. Figure 27-1 and Figure 27-2 In the PBS, BP@PEG and PBP@siR groups, strong red fluorescence of c-caspase-3 appeared. This shows that after the biomimetic nanomaterials PBP@PM and PBP@siR@PM were targeted into the plaque, the anti-oxidative stress and anti-inflammatory effects of BPNSs were fully exerted. It is worth noting that in the co-localization of CD68 / TNF-α and CD68 / c-caspase-3 immunofluorescence, the PBP@siR@PM group had a more obvious relief effect than the PBP@PM group, which may be due to the therapeutic effect brought about by siRNA promoting macrophage efferocytosis.

[0103] Experiment 19: In order to further clarify the mechanism of anti-oxidative stress and anti-inflammatory effects of biomimetic nanomaterials, we detected the expression levels of related pathway proteins in the aorta by WB. Figure 28-1 and Figure 28-2 . The comparison results showed that compared with the PBS, BP@PEG and PBP@siR groups, the expression of anti-inflammatory factors IL-4 and IL-10 was significantly increased in the PBP@PM and PBP@siR@PM groups, while the expression of pro-inflammatory factors IL-6 and TNF-α was significantly decreased in the aorta with plaques. It is worth noting that the expression of IL-10 and IL-6 proteins in the PBP@siR@PM group was different from that in the PBP@PM group, which may be the result of the combined action of siRNA and BPNSs. The NF-κB pathway is a central regulator of cellular inflammation, and phosphorylated IκBα activation further induces inflammatory response. Therefore, we detected the expression of p-IκBα and NF-κB in aortic plaques. The results showed that p-IκBα and NF-κB were expressed at very low levels in the PBP@PM and PBP@siR@PM groups. The above results indicate that the delivery of PBP@PM and PBP@siR@PM into AS plaques can effectively resist oxidative stress and inhibit the activation of NF-κB inflammatory signaling pathway, providing a promising therapeutic strategy for atherosclerotic lesions.

[0104] Experiment 20: The expression level of CaMKIIγ in plaques was detected by CD68 / CaMKIIγ immunofluorescence co-localization. Figure 29-1 and Figure 29-2 The results showed that the red fluorescence in the plaques of the PBP@siR@PM group was significantly weakened, while strong red fluorescence representing CaMKIIγ was observed in the PBS, BP@PEG, PBP@siR, and PBP@PM groups. Since the loss of CaMKIIγ increases the expression of MerTK in macrophages, we evaluated the expression of MerTK. The evaluation results are shown in Figure 2. Figure 30-1 He Ru Figure 30-2 It was found that the expression of MerTK increased significantly after PBP@siR@PM treatment. The results of WB detection of aortic plaque tissue were similar to those of immunofluorescence detection, as shown in Figure 31-1 and Figure 31-2. CaMKIIγ protein decreased by about 60%, while MerTK increased by 80%. Therefore, treatment of AS mice with PBP@siR@PM successfully reduced CaMKIIγ in lesional macrophages and induced an increase in its downstream MerTK.

[0105] The above is only one embodiment of the present invention, and its description is relatively specific and detailed, but it cannot be understood as limiting the scope of the present invention. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the present invention shall be based on the attached claims.

Claims

1. An anti-atherosclerosis biomimetic nano-delivery platform, characterized by: The bionic nano delivery platform is composed of a concentration of 1.0 to 2.5 mg mL -1 Dispersion of black phosphorus nanosheets functionalized with double-terminated amino polyethylene glycol, concentration 0.2-0.5 nmol / mL -1 The small interfering RNA solution and platelet membrane are mixed and prepared; the concentration is 1.0-2.5 mg mL -1 Dispersion of black phosphorus nanosheets functionalized with double-terminated amine polyethylene glycol, concentration 0.2-0.5 nmol mL -1 The volume ratio of the small interfering RNA solution to the platelet membrane is 1 to 2:1:1; Wherein, the concentration is 1.0~2.5mg mL -1 The dispersion of black phosphorus nanosheets functionalized with double-terminated PEG is prepared by adding double-terminated PEG to a concentration of 1.0 to 2.5 mg mL -1 The black phosphorus nanosheet dispersion is stirred in a dark environment for 6 to 8 hours at room temperature with a pH value of 8.0 to 9.0; wherein the mass ratio of the double-terminated amino polyethylene glycol to the black phosphorus nanosheet is 2 to 10:1 to 2.5; The concentration is 0.2-0.5 nmol mL -1 The small interfering RNA solution is a mixture of small interfering RNA and a concentration of 1mmolmL -1 The small interfering RNA is fully dissolved in Tris-HCl buffer, wherein the molar mass ratio of the small interfering RNA to the Tris-HCl buffer is 0.2-0.5:

1.

2. The anti-atherosclerosis biomimetic nano-delivery platform according to claim 1, characterized in that: The platelet membrane is prepared by collecting blood from C57BL / 6 mice, centrifuging at a centrifugal speed of 100-120 g for 15-20 minutes to collect the supernatant, then centrifuging at a centrifugal speed of 800-1000 g for 15-20 minutes to precipitate platelets, resuspending the platelets in PBS containing 1 mM EDTA and protease inhibitors, and then repeatedly freezing and thawing the platelets, and then centrifuging at a centrifugal speed of 8000-10000 g for 10-20 minutes to obtain the platelet membrane.

3. The anti-atherosclerosis biomimetic nano-delivery platform according to claim 1, characterized in that: The black phosphorus nanosheets are synthesized by electrochemically exfoliating black phosphorus crystal blocks; the biomimetic nano delivery platform is firstly prepared by mixing the black phosphorus nanosheets with a concentration of 1.0 to 2.5 mg mL -1 Dispersion of black phosphorus nanosheets functionalized with double-terminated amine polyethylene glycol and concentration of 0.2-0.5 nmol mL -1 The small interfering RNA solution is stirred at room temperature for 5 to 8 hours to mix evenly, and then centrifuged at a centrifugal speed of 5000 to 12000 rpm for 15 to 20 minutes, and filtered to obtain black phosphorus nanosheets loaded with small interfering RNA; then the black phosphorus nanosheets loaded with small interfering RNA are mixed with platelet membranes, and then ultrasonically treated for 2 to 4 minutes at a frequency of 40 to 50 kHz and a power of 100 to 120 W in an ultrasonic water bath, and fused 20 to 30 times through a micro extruder, and then centrifuged at a centrifugal speed of 3000 to 5000 g for 15 to 30 minutes to remove the uncoated membrane, and finally centrifuged at a centrifugal speed of 8000 to 10000 g for 10 to 20 minutes to obtain an anti-atherosclerosis bionic nano delivery platform with targeting ability.

4. The anti-atherosclerosis biomimetic nano-delivery platform according to claim 1 or 3, characterized in that: The small interfering RNA has the following sequence: Sense strand: 5′-AAC GUG GUA CAU AAU GCU ACA-3′ Antisense strand: 5′-UGU AGC AUU AUG UAC CAC GUU-3′.

5. A method for preparing the anti-atherosclerotic bionic nano-delivery platform as claimed in claims 1 to 4, characterized in that: The specific steps include: (1) Precipitate and disperse black phosphorus nanosheets in ultrapure water to obtain a concentration of 1.0 to 2.5 mg mL -1 A dispersion of black phosphorus nanosheets functionalized with double-terminal amino polyethylene glycol is prepared, and then the pH value is adjusted to 8.0-9.0, and then double-terminal amino polyethylene glycol powder is slowly added, and the mixed solution is continuously stirred for 6-8 hours at room temperature in the dark, and after stirring, the mixture is centrifuged at 4-10° C. and 5000-12000 rpm for 15-20 minutes, the supernatant is discarded, and the precipitate is washed to form black phosphorus nanosheets functionalized with double-terminal amino polyethylene glycol; wherein the mass ratio of double-terminal amino polyethylene glycol powder to black phosphorus nanosheets is 2-10:1-2.5; (2) Small interfering RNA with a concentration of 1 mmol mL -1 The Tris-HCl buffer was fully dissolved and prepared to a concentration of 0.2-0.5 nmol / mL -1 siRNA solution; (3) mixing the double-terminated amino-polyethylene glycol-functionalized black phosphorus nanosheet dispersion prepared in step (1) and the small interfering RNA solution prepared in step (2) in a volume ratio of 1 to 2:1, stirring at room temperature for 5 to 8 hours, centrifuging at a centrifugal speed of 5000 to 12000 rpm for 15 to 20 minutes, and then filtering to obtain black phosphorus nanosheets loaded with small interfering RNA; (4) Platelet membranes were prepared by extracting platelets from C57BL / 6 mice and repeated freeze-thaw cycles; (5) The black phosphorus nanosheet loaded with small interfering RNA prepared in step (3) and the platelet membrane prepared in step (4) are mixed in a volume ratio of 1 to 2:1, ultrasonically treated in an ultrasonic water bath at a frequency of 40 to 50 kHz and a power of 100 to 120 W for 2 to 4 minutes, and fused 20 to 30 times by a micro extruder; then, the uncoated membrane is removed by centrifugation at a centrifugal speed of 3000 to 5000 g for 15 to 30 minutes, and finally, the anti-atherosclerotic bionic nano-delivery platform with targeting capability is obtained by centrifugation at a centrifugal speed of 8000 to 10000 g for 10 to 20 minutes.

6. The method for preparing an anti-atherosclerosis biomimetic nano-delivery platform according to claim 5, characterized in that: The black phosphorus nanosheets in step (1) are synthesized by electrochemically exfoliating black phosphorus crystal blocks; in step (1), an ammonia solution is added to adjust the pH to 8.0-9.

0.

7. The method for preparing an anti-atherosclerotic bionic nano-delivery platform according to claim 5, characterized in that: The specific preparation process of the platelet membrane in step (4) is as follows: blood from C57BL / 6 mice is collected, and the blood is centrifuged at a centrifugal speed of 100-120 g for 15-20 minutes, the supernatant is collected, and the platelets are precipitated after centrifugation at a centrifugal speed of 800-1000 g for 15-20 minutes, and the precipitated platelets are resuspended in PBS containing 1 mM EDTA and protease inhibitors, and the platelet membrane is obtained after repeated freeze-thaw cycles for 3-5 times, and finally the platelet membrane is obtained by centrifugation at a centrifugal speed of 8000-10000 g for 10-20 minutes.

8. Use of the anti-atherosclerotic bionic nano-delivery platform according to claims 1 to 7 in therapeutic drugs for atherosclerotic diseases.

9. The use of an anti-atherosclerosis biomimetic nano-delivery platform according to claim 8, characterized in that: The anti-atherosclerotic bionic nano-delivery platform is used in the preparation of intravenous injection for treating atherosclerotic diseases.

10. The use of a biomimetic nano-delivery platform with targeting capability for anti-atherosclerosis according to claim 9, characterized in that: The anti-atherosclerotic bionic nano-delivery platform is used as a single substance of an atherosclerotic disease injection agent, and the single dosage of the injection agent is 100-120 μL, and the concentration is 1.0-1.5 mg kg -1 .

Citation Information

Cited By

  • Bionic black phosphorus nano material as well as preparation and application thereof

    CN121570436A

  • Bionic black phosphorus nanomaterial and preparation and application thereof

    CN121570436B

  • Membrane bionic modified siRNA delivery system as well as preparation method and application thereof

    CN121971408A